Marketresearch.biz reports that the Somatostatin Analogs Market size is expected to be worth around USD 11.4 Billion by 2033, ...

The approval includes multiple strengths of Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection.

Cipla USA Inc., wholly owned subsidiary of Cipla USA has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL ...

Cipla, a major pharmaceutical company, has obtained approval from the US Food and Drug Administration (FDA) to market its ...

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions ...

Drugmaker Cipla on Wednesday announced that the US Food and Drug Administration (USFDA) has granted it final approval for the L ...

The drugmaker said its product is indicated for the treatment of patients with acromegaly and gastroenteropancreatic ...

Mumbai-headquartered pharma major Cipla US arm has secured final approval from the United States Food and Drug Administration USFDA for its Lanreotide Inje ...

Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used ...

Cipla's Lanreotide injection is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic ...

The wholly-owned subsidiary Cipla USA Inc has received the final approval for the Abbreviated New Drug Application (ANDA) of ...

Although the medical condition acromegaly may be fairly rare, for those who do live with the hormone disorder, it can cause a ...